Pfizer Q1 FY21 Share Price & Earnings Call Analysis

9out of 100

Momentum score · price trend

9 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,905 stocks
Last 12 months−31.8%22%
Last 6 months−23.7%15%
Last 3 months−21.9%15%

The price is 41.4% below its all-time high of ₹6,164.2 (6 Sept 2024). Stocks more than 20% below their peak have their score halved, so 18 became 9.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,905 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Pfizer: 0.4 × 22 + 0.4 × 15 + 0.2 × 15 = 18, halved to 9 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 23 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Financials of Pfizer

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Pfizer

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +573531575540547563589538592603642645629
Expenses +391421393387357385399392364393412417393
Operating Profit182111183153189177189146228210230228236
OPM %32%21%32%28%35%32%32%27%38%35%36%35%38%
Other Income +12333644754243432176742-2050
Interest3333722233222
Depreciation26161518141515151614141415
Profit before tax165126201176244203215172426260255192269
Tax %21%26%26%26%27%26%26%26%22%26%26%26%26%
Net Profit +13094149130179151158128331192189142200
EPS in Rs28.3420.4432.5628.4139.1032.9434.6127.8972.3441.9141.3231.0043.68

Financials of Pfizer

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +1,8532,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,520
Expenses +1,4381,5791,6161,4681,5161,5781,5261,7751,6161,5551,5401,616
Operating Profit414433350501566574712836809638742904
OPM %22%22%18%25%27%27%32%32%33%29%33%36%
Other Income +44972321141671838163134185344139
Interest21212111511131589
Depreciation25058636671103109115106626158
Profit before tax2074705175486606426697738247461,016976
Tax %66%35%35%34%35%21%26%21%24%26%24%26%
Net Profit +70305337360429509498613624551768722
EPS in Rs15.2666.6773.6278.7193.79111.29108.77133.90136.38120.52167.79157.92
Dividend Payout %82%22%27%25%24%297%32%26%29%29%98%48%

Financials of Pfizer

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital464646464646464646464646
Reserves1,9272,1182,3732,6372,9663,3502,3472,8193,1623,5504,1724,157
Borrowings +222222633941404170
Other Liabilities +6387228401,0049261,007810997752593653649
Total Liabilities2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922
Fixed Assets +944925902950886973894869749713724678
CWIP133151013180820
Investments43370000000000
Other Assets +1,6141,9232,3432,7393,0543,4322,3693,0303,2443,5164,1804,224
Total Assets2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922

Financials of Pfizer

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +11334532933298323427667356257660968
Cash from Investing Activity +68-701-250-238351,530-469-575-3654-71-562
Cash from Financing Activity +-1-62-83-110-110-164-1,571-181-346-235-205-798
Net Cash Flow181-417-3-17231,690-1,613-88-2675383-392
Free Cash Flow93398394262125343410654292291783944
CFO/OP62%120%146%105%59%93%89%107%81%64%110%105%

Financials of Pfizer

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322620293029182023313126
Inventory Days191167148147189198199173175200214195
Days Payable16515717824521319713010291776889
Cash Conversion Cycle5836-10-696318791107154177132
Working Capital Days7-9-47-57-16-83-14124239
ROCE %24%22%17%21%23%20%23%29%26%22%22%24%

Continue your research

What Pfizer's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Torrent Pharmaceuticals Ltd (Q2 FY27)

    4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect

  • Sakar Healthcare Ltd (Q2 FY27)

    2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se

  • Dr Reddys Laboratories Ltd (Q2 FY27)

    Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre

  • Beta Drugs Ltd (Q2 FY27)

    H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd